What age do you need to be for Mounjaro — and does it change anything?

Is there a minimum age for Mounjaro in the UK?

Yes. The UK licence for tirzepatide covers adults only, which means 18 and above. Below that threshold, the medicine has not been studied in clinical trials sufficient for UK authorisation, and no prescriber working within licensed practice can prescribe it for weight management to someone under that age. This isn't a guideline that clinicians can weigh up and override, it is a hard regulatory boundary set by the MHRA.

It's a question our prescribers hear most weeks, usually from parents who are concerned about a teenager's weight and want to know whether Mounjaro could help. The honest answer is that it cannot, at least not lawfully or with the evidence base to support it. The NHS and NICE guidance on weight management for children and young people points toward structured lifestyle programmes, which remain the appropriate route for under-18s.

The NHS tirzepatide medicines page confirms this restriction clearly, and it applies whether treatment is sought privately or on the NHS. If you are not yet 18, Mounjaro is not an option. You can also read more about whether there is an age limit for Mounjaro in more detail, including a full breakdown of what the age limit for Mounjaro means in practice.

Is there a maximum age, can older adults take Mounjaro?

The UK licence does not set an upper age ceiling. SURMOUNT-1, the pivotal phase-three trial published in the New England Journal of Medicine, included adults across a wide age range, and the licence reflects that broader population. In practice, though, age brings complexity. Kidney function often declines gradually over decades, and tirzepatide is cleared partly through the kidneys; a prescriber will consider this when assessing a patient in their 70s or 80s. Polypharmacy (being on multiple medicines simultaneously) also becomes more likely with age, so a clinical review of current medications matters more, not less.

None of this means older adults cannot use Mounjaro. Many do, safely, when their clinical picture supports it. It means the prescriber's assessment carries extra weight. At nume, every consultation is read by a GPhC-registered Independent Prescriber who considers the individual (age, medical history, current medicines) not just the BMI reading.

For a broader look at how tirzepatide fits into weight management, the Mounjaro treatment overview covers the full picture.

How does age affect the eligibility criteria beyond the licence itself?

Mounjaro's licensed weight-management eligibility runs from a BMI of 30 upwards, or from 27 if at least one weight-related condition is present, conditions such as type 2 diabetes, high blood pressure, or obstructive sleep apnoea. Age can shift this calculation in practical ways. Weight-related conditions accumulate over time; a 55-year-old with a BMI of 28 and both hypertension and dyslipidaemia may well qualify, where the same BMI in a 25-year-old with no comorbidities would not.

NICE's appraisal of tirzepatide (NICE TA1026) sets a higher bar for NHS access (BMI 35 or above with at least one qualifying comorbidity) but private prescribing follows the licensed criteria, which are broader. The same ethnic-background adjustment applies at any age: thresholds sit 2.5 kg/m² lower for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance.

If you want to explore what this means for your specific situation, our FAQs cover eligibility in plain terms, and the practical Mounjaro guidance page gives useful context on what to expect once treatment begins. If you've been wondering whether there are codes for Mounjaro that could reduce the cost, that is also worth checking before you decide on next steps, and you can find out how a code for Mounjaro works and where to get one before committing to a plan.

Does age change how the medicine behaves or what side effects to expect?

The side-effect profile of tirzepatide is broadly consistent across age groups in the trial data. Gastrointestinal effects (nausea, loose stools, reduced appetite, occasional vomiting) are the most commonly reported and tend to be most noticeable in the early weeks or after a dose step-up, regardless of age. They typically ease as the body adjusts.

Where age can matter is in tolerance of those side effects. Severe or prolonged nausea that leads to poor fluid intake is a more serious concern for someone whose kidney function is already reduced. The MHRA and NHS guidance both flag dehydration from GI illness as something to act on promptly rather than push through. Older adults on diuretics or blood-pressure medicines should make sure their prescriber knows, because the combination can compound the risk.

Mounjaro is a Black Triangle (▼) medicine, meaning the MHRA continues to collect safety data after approval. Reporting any unexpected effects via the Yellow Card scheme helps build that evidence base for everyone. If you're weighing up the treatment more broadly, the weight-loss treatment overview sets out the options available through nume. When you're ready to find out whether you're clinically suitable, checking your eligibility through a free consultation is the natural next step.